Literature DB >> 22897785

Milk oral immunotherapy is effective in school-aged children.

Susanna Salmivesi1, Matti Korppi, Mika J Mäkelä, Marita Paassilta.   

Abstract

AIMS: To study the efficacy of oral immunotherapy (OIT) in schoolchildren with cow's milk (CM) allergy (CMA).
METHODS: Twenty-eight children aged 6-14 years with CMA documented by oral challenge were enrolled into a randomized, double-blind, placebo-controlled OIT study. In the active treatment, CM protein amount was increased during 23 weeks from 0.06 mg to a maximum of 6400 mg (200 mL of milk).
RESULTS: Twenty-four (86%) patients completed the protocol: 16/18 in active and 8/10 in placebo groups. All children in the active and 2/3 in the placebo group suffered from symptoms considered by the parents as induced by milk. The children were contacted by phone 12 months later, and 13 (81%) used daily CM or milk products corresponding 6400 mg of CM protein. After double-blind OIT, all 10 children in the placebo group completed successfully an open-label OIT by an identical protocol, and all used daily CM or milk products 6 months later. Three to 3.5 years later, one child more had discontinued daily milk use. Thus, the long-term success rate was 22/28 (79%).
CONCLUSIONS: This placebo-controlled, double-blind study confirmed that OIT was effective in desensitizing schoolchildren with CMA. With occasional exceptions, the reached desensitization sustained for more than 3 years.
© 2012 The Author(s)/Acta Paediatrica © 2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897785     DOI: 10.1111/j.1651-2227.2012.02815.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  21 in total

1.  Milk oral immunotherapy-effective but still experimental.

Authors:  Marita Paassilta; Susanna Salmivesi; Matti Korppi
Journal:  Eur J Pediatr       Date:  2012-10-30       Impact factor: 3.183

Review 2.  The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.

Authors:  Christina S K Yee; Rima Rachid
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

3.  Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy.

Authors:  Stacie M Jones; A Wesley Burks; Corinne Keet; Brian P Vickery; Amy M Scurlock; Robert A Wood; Andrew H Liu; Scott H Sicherer; Alice K Henning; Robert W Lindblad; Peter Dawson; Cecilia Berin; David M Fleischer; Donald Y M Leung; Marshall Plaut; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2016-03-09       Impact factor: 10.793

Review 4.  Sublingual (SLIT) versus oral immunotherapy (OIT) for food allergy.

Authors:  Emily C McGowan; Robert A Wood
Journal:  Curr Allergy Asthma Rep       Date:  2014-12       Impact factor: 4.806

Review 5.  Oral immunotherapy for the treatment of food allergy.

Authors:  Philippe Begin; R Sharon Chinthrajah; Kari C Nadeau
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Patient-Centered Outcomes in Food Allergy.

Authors:  Brooke I Polk; Chitra Dinakar
Journal:  Curr Allergy Asthma Rep       Date:  2017-06       Impact factor: 4.806

Review 7.  Oral Immunotherapy for Treatment of Immunoglobulin E-Mediated Food Allergy: The Transition to Clinical Practice.

Authors:  Giovanni B Pajno; Linda Cox; Lucia Caminiti; Vincenzo Ramistella; Giuseppe Crisafulli
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2014-06-01       Impact factor: 1.349

Review 8.  Current and Emerging Therapies for IgE-Mediated Food Allergy.

Authors:  Robbie D Pesek; Stacie M Jones
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

9.  New modalities of allergen immunotherapy.

Authors:  Manish Ramesh; Merhunisa Karagic
Journal:  Hum Vaccin Immunother       Date:  2018-09-14       Impact factor: 3.452

Review 10.  The Role of Eosinophils in Immunotherapy.

Authors:  Joseph Cafone; Melanie A Ruffner; Jonathan M Spergel
Journal:  Curr Allergy Asthma Rep       Date:  2020-01-07       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.